A Phase Ib Study of Abiraterone Plus Docetaxel for mCRPC

Edwin M. Posadas, MD, FACP

Edwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Clinical Pearls

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

  • Some oncologists are unsure about whether abiraterone or docetaxel is more appropriate for patients with mCRPC. Combining the agents could maximize outcomes for patients.
  • This phase Ib showed that the combination was well tolerated.

More about this study > >